July 2nd 2024
Kisunla (donanemab-azbt) is now approved by the FDA for adults with early symptomatic Alzheimer disease.
The Science, Ethics, and Art of Disclosing a Dementia Diagnosis
How can you communicate the diagnosis in a way that relieves suffering and helps patients and their caregivers prepare for the future?
Read More